

**GOVERNMENT OF INDIA  
HEALTH AND FAMILY WELFARE  
LOK SABHA**

STARRED QUESTION NO:216

ANSWERED ON:15.12.2004

ANTI-RABIES VACCINE

Adhalrao Patil Shri Shivaji;Gaikwad Shri Eknath Mahadeo

**Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:**

- (a) whether a new indigenously developed and produced anti-rabies vaccine has been launched by a Pune-based Institute with the approval of the Central Government;
- (b) if so, the details of the vaccine, its efficacy as established on the basis of tests conducted on humans and otherwise; and
- (c) the estimated cost of production and the approved sale prices thereof?

**Answer**

THE MINISTER OF HEALTH AND FAMILY WELFARE (DR. ANBUMANI RAMADOSS)

(a)to(c): A statement is laid on the Table of the House.

STATEMENT REFERRED TO IN REPLY TO LOK SABHA STARRED QUESTION NO. 216 FOR 15TH DECEMBER, 2004

Based on the satisfactory evaluation of quality, safety and efficacy, the Drug Controller General of India has approved the Anti-Rabies Vaccine based on human diploid cell lines, using Pitman Moore Strain (both liquid and freeze dried) to be produced indigenously by M/S Serum Institute of India, Pune, for marketing in the country. The clinical trial carried out with the vaccine has been found to be Sero Protective Level more than 0.5 IU/ml of Rabies Antibodies. The vaccine was reported to be of standard quality by the National Control Laboratory situated at CRI, Kasauli, before it was marketed in the country as a pre-requisite criteria for release of vaccines.

Serum Institute of India Limited, Pune, is marketing this vaccine under the brand name `Rabivax`. While the estimated cost of the production is not available, the present maximum retail price of Rabivax is Rs.293 (excluding taxes as applicable), per vial.